ELDN Overview

Market Activity: Several small- and mid-cap stocks experienced notable gains in after-hours trading, driven by investor sentiment and sector momentum rather than new company news.

Top Gainers: Spyre Therapeutics, Inc. (SYRE) led the gains with a 4.99% increase, followed by The Oncology Institute, Inc. (TOI) with a 5.49% rise, both without any fresh updates.

Sector Trends: Aurora Cannabis Inc. (ACB) and Lexeo Therapeutics, Inc. (LXEO) also saw gains, benefiting from renewed momentum in the cannabis and biotech sectors, respectively, despite no new announcements.

Significant Developments: Solid Biosciences Inc. (SLDB) recently highlighted a key milestone regarding Duchenne muscular dystrophy, which has positively influenced its stock performance, even without new news on the trading day.

Q3 Financial Performance: Eledon Pharmaceuticals reported a Q3 GAAP EPS of -$0.21, indicating a loss for the quarter.

Cash Position: As of September 30, 2025, the company had $93.4 million in cash, cash equivalents, and short-term investments, down from $140.2 million at the end of 2024.

Stock Movement: The company's stock dropped by 10% following a recent stock offering.

Clinical Trial Updates: Eledon Pharmaceuticals discussed the results of its Phase II BESTOW trial and advancements in transplantation immunosuppression.

Stock Performance: Eledon Pharmaceuticals (NASDAQ: ELDN) experienced a significant drop in stock price, down 59.03% to $1.68, with a trading volume of 15.72 million shares compared to its average of 1.24 million.

Phase 2 Trial Results: The Phase 2 BESTOW trial for tegoprubart, aimed at preventing organ rejection in kidney transplant patients, did not show significant improvements in estimated glomerular filtration rates (eGFR) compared to the standard immunosuppressant tacrolimus.

Efficacy and Safety Findings: Despite missing the primary efficacy endpoint, tegoprubart demonstrated the highest mean eGFR reported in kidney transplant trials and showed lower rates of delayed graft function and shorter dialysis duration compared to tacrolimus.

Future Development Plans: Eledon plans to advance tegoprubart into Phase 3 development after discussions with regulators, supported by approximately $93.4 million in cash reserves expected to last until late 2026.